Ketamine plus talk therapy: a new hope for stubborn depression?
NCT ID NCT06138691
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether combining intravenous ketamine with a specific talk therapy called RO DBT is safe and feasible for adults with treatment-resistant depression. Sixteen participants received four weekly ketamine infusions plus four months of RO DBT. The main goal was to see if the combination is practical and safe, and to measure changes in depressive symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketamine infusion plus radically open dialectical behavior therapy (RO DBT)
- What this could lead to
- If this combination proves safe and feasible, it could point toward a new treatment approach for people with depression that hasn't responded to other therapies.
- What could go wrong
- This is a very small, early-phase study with only 16 participants. It focuses on safety and feasibility, not on proving the treatment works. Ketamine can cause side effects like dissociation or nausea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
16 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Feb 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males and females aged 18-65 * Moderate to severe persistent depression \[treatment resistant depression - TRD\] (exhibiting 2+ unipolar major depression episodes (non-delusional) with prior treatment non-response to antidepressant or psychosocial treatment * Treatment-resistant depression: defined as unipolar major depressive disorder, non-delusional (diagnosed by SCID-5, Structured Clinical Interview for the DSM ) that persists despite ≥ 2 adequate antidepressant trials of different classes in the current episode; including at least one evidence-based second-line treatment in the current episode (including serotonin norepinephrine reuptake inhibitors, bupropion, tricyclics, monoamine oxidase inhibitors, or augmentation with an atypical antipsychotic, stimulant, bupropion, lithium, or Triiodothyroinine) higher proportion of OC (over controlled) words endorsed compared to UC (Under controlled) words on the Word Pairs Checklist * no current or past psychosis * English speaking * Able to attend in-person behavioral sessions and ketamine/therapy visits * Willingness to have RO DBT-A as only psychosocial treatment engaged in (medication treatment may continue-but see below for exclusion) Exclusion Criteria: * Outside age range * Significant neurological condition (i.e., seizure, stroke, severe head injury) or mental retardation (IQ\<70) * Current or recent substance use disorder, actively suicidal or homicidal (e.g., requires hospitalization) * Use of naltrexone, memantine or medication considered contraindicated with ketamine * Baseline systolic BP \> 150 systolic or 90 diastolic at evaluation. Participants who initially present with elevated blood pressure may be re-assessed; and if needed, referred to their healthcare provider for hypertension management * Taking more than 2 adequately-dosed oral antidepressants * Inability to understand, speak and read English sufficiently * Not be pregnant or at risk of becoming pregnant * Medical conditions or medication usage that in the judgement of the investigators puts the patient at unreasonable safety risk * First degree relative with a psychotic diagnosis involving hallucinations, delusions, or disorganized thinking and speech (e.g. schizophrenia, schizoaffective disorder, etc)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Treatment-resistant depression are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray aims to lift depression that antidepressants miss
- Can a computer model outsmart depression in older adults?
- Can an anesthetic lift severe depression?
- Can pairing ketamine with talk therapy beat depression alone?
- Can a psychedelic drug lift depression that won't budge?
- Can a 6,000-Person study unlock personalized depression care for asians?